Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.58 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7350274 | 1.00 | PDE5A (0.58) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL5595379 | 0.87 | PDE5A (0.66) | PDE5A | |
| SCHEMBL7346033 | 0.87 | PDE5A (0.66) | PDE5A | |
| SCHEMBL5595341 | 0.84 | PDE5A (0.61) | PDE5A | |
| SCHEMBL7347444 | 0.84 | PDE5A (0.61) | PDE5A | |
| SCHEMBL3841327 | 0.83 | PDE5A (0.59) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3836975 | 0.80 | PDE5A (0.76) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL7795495 | 0.77 | NPC1 (0.48) | PDE5A | |
| SCHEMBL3842772 | 0.77 | PDE5A (0.75) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL7348770 | 0.75 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365806-A2 | USE OF NO ACTTIVATORS FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2003-12-03 | — | — | EP | claimed |
| EP-0793498-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 2002-12-11 | — | — | EP | claimed |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| WO-2001078781-A2 | METHODS FOR PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2001-10-25 | — | — | WO | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| WO-1993007149-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | claimed |
| EP-1331950-B1 | EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | disclosed |
| US-6992070-B2 | Methods and compositions for nucleic acid delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050004222-A1 | Methods for prevention and treatment of gastrointestinal disorders | JOHNS HOPKINS UNIVERSITY | 2005-01-06 | — | — | US | disclosed |
| US-20040214831-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2004-10-28 | — | — | US | disclosed |
| US-6774128-B2 | ADMINISTERING TO THE MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND THAT INCREASES NITRIC OXIDE (NO) ACTIVITY AS MEASURED IN A STANDARD GASTRIC EMPTYING ASSAY | JOHNS HOPKINS UNIVERSITY | 2004-08-10 | — | — | US | disclosed |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | JOHNS HOPKINS UNIVERSITY | 2002-07-18 | — | — | US | disclosed |
| WO-2002030470-A1 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | JOHNS HOPKINS UNIVERSITY (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6100270-A | Bicyclic heterocyclic compounds for the treatment of impotence | PFIZER INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| WO-1993007149-A1 | PYRAZOLOPYRIMIDINONE ANTIANGINAL AGENTS | PFIZER LIMITED (GB) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004222-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885PDE1A 1228/4885PDE1B 1857/4885 |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885PDE1A 1228/4885PDE1B 1857/4885 |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | TNNC1, TNNI3, TNNT2 | PDE5A 2130/4885PDE1A 1991/4885PDE1B 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.